ENTRY       D00275                      Drug
NAME        Cisplatin (JP17/USP/INN);
            Platinol (TN)
PRODUCT     PLATINOL-AQ (Corden Pharma Latina S.p.A.) a043dd33-3d1d-4884-bb75-80f221e749ba
            PLATINOL (Corden Pharma Latina S.p.A.) b2a8e240-5e93-4a58-9ba2-688a87a5e20c
            CISPLATIN (WG Critical Care) 2bf8d2fb-80c8-401d-8e9b-d58463f5e954
  GENERIC   CISPLATIN (Accord Healthcare) b2b029f5-0d7e-4e7f-accc-b722aec34c68
            CISPLATIN (Alvogen) 61fc9585-d1db-6c41-eb05-8c96d811b2ec
            CISPLATIN (Athenex Pharmaceutical Division) b822ef6e-fb50-4c86-843e-d656e38872d1
            CISPLATIN (BluePoint Laboratories) a60c5173-6bc0-4c9d-9674-b3f4d68f79ba
            CISPLATIN (Fresenius Kabi USA) de6302d5-85f0-4116-a709-57826c2c84fe
            CISPLATIN (Gland Pharma Limited) a32820f7-9ff6-4c13-a96a-4483a943fe82
            CISPLATIN (Mylan Institutional LLC) 64975f5d-0eca-4998-8a72-06eec98285eb
            CISPLATIN (Pfizer Laboratories Div Pfizer) 199a6ab3-9b00-49fc-90d4-644d58141235
            CISPLATIN (Teva Parenteral Medicines) a440f077-46f6-4688-a209-65bce38d1c92
FORMULA     PtCl2. 2NH3
EXACT_MASS  298.9556
MOL_WEIGHT  300.051
CLASS       Antineoplastic
             DG01679  Platinum compound
REMARK      Same as: C06911
            Therapeutic category: 4291
            ATC code: L01XA01
            Chemical group: DG02146
ACTIVITY    Antineoplastic, Cell growth inhibitor
  DISEASE   Bladder cancer [DS:H00022]
COMMENT     platinum compound
            DNA alkylator
TARGET      DNA
METABOLISM  Transporter: SLC22A2 [HSA:6582]
INTERACTION Genomic biomarker: TPMT [HSA:7172]
STR_MAP     map07040  Antineoplastics - alkylating agents
OTHER_MAP   map01524  Platinum drug resistance
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XA Platinum compounds
                 L01XA01 Cisplatin
                  D00275  Cisplatin (JP17/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D00275  Cisplatin (JP17/USP/INN)
            Target-based classification of drugs [BR:br08310]
             Others
              Nucleic acid
               DNA
                Cisplatin
                 D00275  Cisplatin (JP17/USP/INN)
            Cytochrome P450 interactions [BR:br08309]
             Transporter substrates
              SLC22A2
               Cisplatin
                D00275  Cisplatin (JP17/USP/INN)
              MATE1
               Cisplatin
                D00275  Cisplatin (JP17/USP/INN)
              MATE2
               Cisplatin
                D00275  Cisplatin (JP17/USP/INN)
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00275  Cisplatin
            Antineoplastics [br08340.html]
             D00275
            Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
             Polymorphisms and germline mutations
              D00275
DBLINKS     CAS: 15663-27-1
            PubChem: 7847341
            ChEBI: 27899
            DrugBank: DB00515
            PDB-CCD: CPT
            NIKKAJI: J277.914E
ATOM        5
            1   Z   Pt   34.5801  -25.8301
            2   X   Cl   35.9846  -25.8301
            3   X   Cl   34.5743  -27.2286
            4   N0  N    31.9200  -25.8300
            5   N0  N    33.8100  -24.0800
BOND        2
            1     1   2 1
            2     1   3 1
///
